Members of the multidisciplinary care team who diagnose and manage NSCLC must take into consideration histological subtypes and molecular/biomarker analysis that guide appropriate treatment decisions to individualize treatment approaches and improve patient outcomes. Clinicians also need to remain apprised of emerging data offering additional treatment options for NSCLC, specifically in the advanced stage when the disease is typically diagnosed.
Through a case-based approach, this Virtual Grand Rounds will address educational and performance gaps related to the histological and pathological parameters and biomarkers that guide clinical decisions on the appropriate treatment of patients with NSCLC and as a result, help participants make highly informed decisions for their patients.